EP
EDIT icon

Eversept Partners’s Editas Medicine EDIT Stock Holding History

Eversept Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$2.05M – 115
2021
Q3 		$2.05M Buy
+50,000
New +$2.74M 0.14% 77

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Eversept Partners's EDIT Position: Q2 2026 in Review

Eversept Partners increased its Editas Medicine (EDIT) stake by 58% in Q2 2026, buying an estimated $491K and bringing the position to 458,809 shares worth $1.49M. The position accounts for 0.08% of the portfolio, ranked #98.

Eversept Partners first reported a position in EDIT in Q4 2025 and has held it in 3 quarters since. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Eversept Partners held 458,809 shares of Editas Medicine worth $1.49M as of Q2 2026.
  • Eversept Partners bought 167,890 Editas Medicine shares in Q2 2026, an estimated $491K.
  • Editas Medicine made up 0.08% of Eversept Partners's portfolio in Q2 2026, its #98 holding.
  • Eversept Partners first reported a position in Editas Medicine in Q4 2025 and has held it in 3 quarters since.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.